# India API Market > India API Market Research Report Information By Business Mode (Captive API and Merchant API), By Synthesis Type (Synthetic and Biotech), By Drug Type (Generic and Branded), By Application (Cardiology, Oncology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Other Applications), - India Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.76% - **2024:** $ 8 Billion - **2025:** $ 8.33 Billion - **2035:** $ 12 Billion - **Key Players:** Companies such as Tata Consultancy Services (IN), Infosys (IN), Wipro (IN), HCL Technologies (IN), Tech Mahindra (IN), Cognizant Technology Solutions (US), Accenture (IE), IBM (US), Oracle (US) are some of the major participants in the global market. **Report ID:** MRFR/Pharma/19812-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** June 12, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-api-market-21362 --- ## Market Summary ## **India API Market Overview** As per MRFR analysis, the India API Market Size was estimated at 16.86 (USD Billion) in 2024. The India API Market Industry is expected to grow from 18.29 (USD Billion) in 2025 to 38.13 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.50% during the forecast period (2025 - 2034).  The rising cases of chronic diseases, together with the growing importance of generics, are two market drivers driving the growth of the India API industry. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review The Indian Government provided INR 9940 crores as an aid package in their March meeting of 2020 to boost domestic production and exports of bulk drugs. The Government has also approved INR 6940 crore for a production-based incentive scheme towards encouraging the manufacturing of key KSMs, Drug intermediates, and APIs within the country. July 2022 saw Piramal Pharma Limited’s Pharma Solutions business launched its new active pharmaceutical ingredient (API) plant in Aurora, Ontario among the leading contract development and manufacturing organizations (CDMO). In March 2022 India started manufacturing locally thirty-five active pharmaceutical ingredients (APIs), which until then were imported from China at ninety percent under the PLIs. Glenmark launched Teneligliptin + Dapagliflozin combination therapy for adult patients suffering from type-2 diabetes in October 2022. In October 2021, Natco Pharma similarly introduced Trifluridine and Tipiracil fixed-dose combination under the brand name Tipanat; it is an antineoplastic nucleoside that has been approved by US FDA/IND to be used in advanced gastric and colorectal cancer. Hemmo Pharmaceuticals Pvt., Ltd was acquired fully by Piramal Pharma Solution for INR 775 crores ($85 million approx.) in March 2021. This acquisition signifies PPS’s entry into peptide API development and manufacturing, thus supplementing its existing services portfolio while it continues expanding its footprint as a CDMO leader. Mankind Pharma launched over a hundred DMF-quality medicines into the Indian market in April this year. This is part of their program aimed at ensuring access to international standard drugs wherever people may live on Earth. India remains a global leader in providing generic drugs that conform to stringent DMF quality norms prescribed for Active Pharmaceutical Ingredients (APIs). DMF quality API in the Indian market is manufactured in a USFDA-approved plant.  Therefore, the final medicine that comes to people is of the best quality compared to other medicines, and it has better efficacy. The quality, safety, and effectiveness of medicines in the USA are tested by USFDA through DMF (Drug Master File). A drug Master File (DMF) contains all information about an API (Active Pharmaceutical Ingredient/Raw material for medicine). ## **API Market Trends** The elderly population is more susceptible to chronic illnesses, including arthritis, neurological and cardiovascular conditions, and so on, because of their compromised immune systems, which is driving the market CAGR. Expanding markets are anticipated as aging affects multiple cellular processes and increases the risk of neurodegeneration. About 18,896 individuals had a Parkinson's disease screening in May of 2021. Approximately 42.3% of every 100,000 individuals had the illness.  The prevalence was 308.9 per 100,000 adults over 60, according to the same source, which suggests that the frequency of the condition is rising. It follows that a greater need for different treatment drugs and therapies will likely arise due to the high incidence of Parkinson's disease among the elderly. Due to this, API demand is anticipated to rise faster than market expansion. The increasing prevalence of chronic illnesses is expected to increase the demand for pharmaceutical treatments, which will fuel the market's growth for active pharmaceutical ingredients over the projected period. For instance, according to 2022 statistics released by IDF, over 74 million individuals in India had diabetes in 2021; by 2030, this figure is expected to rise to 92.9 million.  Furthermore, a few of the strategic initiatives being implemented to maintain market stability include partnerships, acquisitions, geographical expansions, and the introduction of new pharmaceuticals and biological products. Additionally, advancements in medical technology, a rise in the quantity of public and private organizations' awareness-raising initiatives, and a rise in government funding are the elements that will propel the market for [active pharmaceutical ingredients](../../../reports/active-pharmaceutical-ingredients-market-1385) (APIs).  The market for API will grow as a result of changes in lifestyle, increased levels of disposable money, and an increase in the frequency of seizures. Thus, driving the API market revenue. ## **API Market Segment Insights** ### **API Business Mode Insights** The India API market segmentation, based on business mode, includes Captive API and Merchant API. The captive API segment dominated the market mostly. The availability of raw resources and the significant investments made by major participants in the industry to construct advanced manufacturing facilities are projected to drive its growth over the coming years. Additionally, it appears that important stakeholders prioritize internal manufacturing over outsourcing in light of recent events and actions. ### **API Synthesis Type Insights** The India API market segmentation, based on Synthesis Type, includes Synthetic and Biotech. The synthetic category generated the most income. This market is expanding since it is simple to create synthetic chemicals. Pharmaceutical businesses might find a cost-effective solution in synthetic APIs when it comes to generating pharmaceuticals in large numbers. For this reason, they are in great demand in the pharmaceutical industry. The growing demand for these components is expected to fuel the growth of the API market. **Figure 1: India API Market, by Synthesis Type, 2023 & 2032 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **API Drug Type Insights** The India API market segmentation, based on Drug Type, includes Generic and Branded. The branded category generated the most income. Many firms are motivated to introduce novel pharmaceuticals onto the market as a result of significant R&D initiatives that concentrate on the creation of numerous creative and cost-effective goods.  The manufacturing of branded API is expected to accelerate due in large part to the growing therapeutic application of innovative generation ingredients, which includes peptides and high potency chemicals. ### **API Application Insights** The India API market segmentation, based on application, includes Cardiology, Oncology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Other Applications. The oncology category generated the most income. The growing number of cancer cases, more knowledge of diseases and treatments related to the early-onset cancer epidemic, and a rise in product launches are the factors driving the growth of the market.  In 2020, 1,324,413 new cases of cancer were reported in India (678,383 females and 646,030 males), according to the GLOBOCAN 2020 factsheet. Therefore, the demand for developing effective medications is increased by the anticipated rise in the number of cancer patients. It is, therefore, expected that this will increase API demand and spur market expansion. ### **API Country Insights** The rising frequency of infectious, genetic, cardiovascular, and other chronic conditions, the growing elderly population, the growing acceptance of biologics and biosimilars, and the country's increased manufacture of generic pharmaceuticals are all driving market expansion.  In terms of volume, India's pharmaceutical sector is the world's third-largest. India maintains around 250 facilities that have been approved by the USFDA and UKMHRA, and it supplies generic drugs to millions of people around the world at low prices.  Moreover, the increased prevalence of infectious, genetic, and other chronic diseases like cancer, diabetes, and neurological disorders is the primary driver of market expansion. For instance, according to IDF's 2022 statistics, over 74 million individuals in India had diabetes in 2021, with the figure expected to rise to 92.9 million by 2030. As a result of the country's high diabetic population, the company is focusing on producing innovative and safe drugs that require a large amount of API, which is driving market growth. **API Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the API market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, API industry must offer cost-effective items. Major players in the API market are attempting to increase market demand by investing in research and development operations, including Aurobindo Pharma, Boehringer Ingelheim GmbH, Novartis AG, Lupin Ltd, BASF SE, Viatris Inc., Sanofi Inc., GlaxoSmithKline PLC, Pfizer Inc., Dr. Reddy's Laboratories Ltd, and Sun Pharmaceutical Industries Ltd. **Key Companies in the API market include** - [Aurobindo Pharma](https://www.aurobindo.com/) - Boehringer Ingelheim GmbH - Novartis AG - Lupin Ltd - BASF SE - Viatris Inc. - Sanofi Inc. - GlaxoSmithKline PLC - Pfizer Inc. - Dr. Reddy's Laboratories Ltd - Sun Pharmaceutical Industries Ltd. ## India API Market Industry Developments - **Q2 2024: Lupin launches generic version of Spiriva in India** Lupin announced the launch of its generic version of Spiriva (Tiotropium Bromide Inhalation Powder) in India, expanding its respiratory portfolio and strengthening its position in the domestic API market. - **Q2 2024: Sun Pharma receives US FDA approval for generic drug manufactured in India** Sun Pharmaceutical Industries received approval from the US FDA for its generic version of a key cardiovascular drug, manufactured at its Indian API facility, marking a significant regulatory milestone. - **Q3 2024: Dr. Reddy’s Laboratories opens new API manufacturing facility in Hyderabad** Dr. Reddy’s Laboratories inaugurated a new API manufacturing plant in Hyderabad to boost production capacity and support global supply chains. - **Q3 2024: Aurobindo Pharma acquires API assets from Veritaz Healthcare** Aurobindo Pharma completed the acquisition of select API manufacturing assets from Veritaz Healthcare, aiming to enhance its product portfolio and manufacturing capabilities. - **Q4 2024: Biocon partners with Syngene to develop novel APIs for oncology** Biocon announced a strategic partnership with Syngene International to co-develop and manufacture novel APIs targeting oncology therapeutics. - **Q4 2024: Glenmark Pharmaceuticals receives DCGI approval for new API facility in Gujarat** Glenmark Pharmaceuticals received approval from the Drug Controller General of India (DCGI) for its newly constructed API manufacturing facility in Gujarat. - **Q1 2025: Cipla secures major API supply contract with European pharma company** Cipla signed a multi-year API supply agreement with a leading European pharmaceutical company, strengthening its export business. - **Q1 2025: Alkem Laboratories raises $100 million in funding to expand API production** Alkem Laboratories completed a $100 million funding round to support the expansion of its API manufacturing operations in India. - **Q2 2025: Zydus Lifesciences launches new API for diabetes treatment** Zydus Lifesciences introduced a new API for diabetes management, aiming to address growing demand in both domestic and international markets. - **Q2 2025: Laurus Labs announces partnership with global biotech firm for API innovation** Laurus Labs entered into a partnership with a global biotech company to co-develop innovative APIs for next-generation therapeutics. - **Q3 2025: Torrent Pharmaceuticals appoints new CEO to lead API division** Torrent Pharmaceuticals announced the appointment of a new CEO for its API division, signaling a strategic focus on growth and innovation. - **Q3 2025: Strides Pharma Science receives regulatory approval for new API manufacturing unit** Strides Pharma Science obtained regulatory clearance for its newly established API manufacturing unit, expanding its production footprint in India. ## **API Market Segmentation** ### **API Business Mode Outlook** ### **API Synthesis Type Outlook** ### **API Drug Type Outlook** ### **API Application Outlook** ## Market Drivers ### Growing Export Opportunities The India Api Market is poised to capitalize on the growing global demand for APIs, particularly in emerging markets. With a robust manufacturing base and competitive pricing, Indian API producers are increasingly exporting their products to regions such as Africa, Southeast Asia, and Latin America.   Recent statistics indicate that India's API exports have surged, with a growth rate of approximately 20% year-on-year. This trend is expected to continue as international markets seek reliable suppliers of high-quality APIs. The expansion of export opportunities not only enhances the revenue potential for Indian manufacturers but also solidifies the country's position as a key player in the global API supply chain.   - According to World Bank Health Data, global healthcare expenditure continues to rise steadily, surpassing USD 9 trillion annually, increasing worldwide demand for affordable pharmaceutical ingredients and medicines. India’s pharmaceutical exports reached more than 200 countries, while API export growth remains strong due to competitive manufacturing costs, helping Indian suppliers strengthen their position across emerging healthcare markets globally. ### Rising Demand for Biopharmaceuticals The India Api Market is experiencing a notable increase in the demand for biopharmaceuticals, driven by a growing prevalence of chronic diseases and an aging population. As healthcare systems evolve, there is a shift towards biologics, which are often more effective than traditional small-molecule drugs.   According to recent data, the biopharmaceutical sector in India is projected to grow at a compound annual growth rate (CAGR) of approximately 15% over the next five years. This trend is likely to bolster the API market, as manufacturers adapt to produce more complex molecules. The increasing focus on personalized medicine further emphasizes the need for innovative APIs, positioning the market as a critical player in the global biopharmaceutical landscape.   - Research available through PubMed highlights that biologics now account for a rapidly increasing share of modern therapeutic development, particularly for oncology and autoimmune diseases. More than 30% of newly approved drugs globally are biologic-based therapies, encouraging Indian manufacturers to expand advanced API and biopharmaceutical production capabilities to meet rising global demand for complex and high-value treatments. ### Focus on Sustainable Manufacturing Practices Sustainability is becoming a central theme within the India Api Market, as manufacturers increasingly adopt eco-friendly practices. The push for greener production methods is driven by both regulatory pressures and consumer demand for sustainable products. Companies are investing in technologies that minimize waste and reduce energy consumption, aligning with global sustainability goals.   The Indian government is also promoting initiatives that encourage sustainable practices in the pharmaceutical sector. As a result, the market is likely to see a shift towards more sustainable manufacturing processes, which could enhance competitiveness and appeal to environmentally conscious consumers. ### Government Policies Supporting API Production The Indian government has implemented various policies aimed at enhancing domestic API production, which is crucial for the India Api Market. Initiatives such as the Production-Linked Incentive (PLI) scheme encourage manufacturers to increase their output of critical APIs. This policy is designed to reduce dependency on imports, particularly from countries like China, which has historically dominated the API supply chain.   The PLI scheme is expected to inject substantial investment into the sector, potentially exceeding USD 1 billion over the next few years. Such government support not only fosters growth within the market but also aims to ensure a stable supply of essential medicines for the domestic market. ### Increased Investment in Research and Development Investment in research and development (R&D) is a pivotal driver for the India Api Market, as companies strive to innovate and enhance their product offerings. The Indian pharmaceutical sector has seen a surge in R&D spending, with estimates suggesting that it could reach USD 5 billion by 2026. This focus on R&D enables manufacturers to develop novel APIs that meet the evolving needs of healthcare providers and patients.   Furthermore, collaborations between academia and industry are becoming more prevalent, fostering an environment conducive to innovation. As a result, the market is likely to benefit from a pipeline of new products that can address unmet medical needs and improve patient outcomes. ## Future Outlook The India API Market size is projected to reach USD 236.66 Billion by 2035, growing at a CAGR of 9.32%, driven by increasing pharmaceutical demand, technological advancements, and regulatory support. **New opportunities:** - Expansion of biopharmaceutical production facilities Investment in green chemistry for sustainable API manufacturing Development of digital platforms for API [supply chain management](https://www.marketresearchfuture.com/reports/supply-chain-management-market-21742) By 2035, the India API market is expected to achieve robust growth, positioning itself as a global leader. ## Segment Insights ### By Application: Mobile Applications (Largest) vs. Cloud Computing (Fastest-Growing) Several application segments are vying for dominance, with Mobile Applications leading the pack in the India API Market with a 38% share, driven by their widespread adoption across various sectors. The surge in mobile device usage, coupled with the impact of digital transformation initiatives, has solidified the position of Mobile Applications as a vital segment. Cloud Computing is also making its mark and is poised for rapid growth as businesses increasingly look to leverage cloud-based solutions for scalability and flexibility in their operations. HCL Technologies continues expanding digital healthcare and enterprise API integration solutions that support mobile-first pharmaceutical and healthcare ecosystems. India had over 750 million smartphone users in 2025, while mobile internet penetration exceeded 70%, significantly increasing demand for API-enabled mobile applications across healthcare, pharmaceutical distribution, and patient engagement platforms. ### By End Use Industry: Healthcare (Largest) vs. Telecommunications (Fastest-Growing) The distribution of market share among end-use industries reveals that the Healthcare sector holds the largest share in the India API market at 42%, driven by the surging demand for pharmaceuticals and biopharmaceuticals. This is driven by the increasing healthcare expenditure and the focus on innovative drug development. Following closely, the Telecommunications industry has emerged as a significant player, capitalizing on the growing use of APIs for digital solutions and mobile applications. Tech Mahindra is strengthening healthcare digital transformation services through cloud-enabled pharmaceutical platforms and connected healthcare solutions. India’s healthcare industry is projected to surpass USD 610 billion by 2026, while pharmaceutical demand continues rising due to expanding healthcare access, increasing chronic disease prevalence, and greater investment in advanced drug development and API manufacturing capabilities. ### By Deployment Model: Cloud-Based (Largest) vs. Hybrid (Fastest-Growing) The deployment model segment in the India API market is shaped by distinct preferences for On-Premises, Cloud-Based, and Hybrid solutions. Currently, Cloud-Based models dominate the landscape with a 45% share, reflecting a significant portion of the overall market, driven by the increasing preference for scalable and cost-effective solutions among businesses. Following this, Hybrid deployments emerge as a significant player, attracting organizations that require a combination of both on-premise and cloud elements to optimize their operations while ensuring security and compliance. As enterprises continually adapt to rapidly changing technological environments, growth drivers for this segment include the surge in digital transformation initiatives and the accelerating adoption of cloud technologies. Businesses are increasingly recognizing the advantages of hybrid models that offer flexibility and customization. The rising popularity of remote work coupled with the demand for agile and responsive IT architectures further boosts the hybrid deployment model, making it the fastest-growing segment in the market. Cognizant Technology Solutions is accelerating cloud modernization initiatives for pharmaceutical and healthcare enterprises through scalable API management solutions. Industry studies indicate that over 65% of healthcare and life-science organizations are prioritizing cloud-based infrastructure adoption to improve operational flexibility, regulatory compliance, and real-time data integration across pharmaceutical manufacturing and distribution networks. ### By Type of API: Open API (Largest) vs. Partner API (Fastest-Growing) The distribution of market share among different types of APIs reveals that Open APIs hold a significant portion of the India API market at 40%, reflecting their popularity and adoption across various industries. On the other hand, Partner APIs, which allow integration with third-party applications, are showing a rapid increase in their share, indicating a growing trend toward collaboration and partnership in the digital landscape. This shift is driving more businesses to invest in and develop Partner APIs as part of their growth strategies. As the demand for interoperability and seamless integration rises, the growth of Partner APIs is supported by advancements in technology and increased focus on enhancing user experiences. Companies are prioritizing the development of Open APIs to foster innovation while Partner APIs are gaining traction as organizations look to capitalize on external partnerships. This trend reflects a significant evolution in how companies are leveraging APIs to maximize functionality and reach in an increasingly competitive market. Accenture is supporting enterprises through open digital ecosystems and interoperable API-driven healthcare platforms. Research shows that organizations implementing open API frameworks can improve system integration efficiency by over 50%, enabling pharmaceutical companies to accelerate innovation, enhance collaboration, and improve digital connectivity across supply chains and healthcare delivery systems. ### By Technology: RESTful API (Largest) vs. GraphQL API (Fastest-Growing) In the India API market, RESTful APIs hold the largest share at 48%, dominating the landscape due to their ease of use, scalability, and widespread adoption across various industries. Conversely, GraphQL API is emerging rapidly, gaining traction for its flexibility and efficiency in data fetching, making it a favorite among modern application developers. As companies shift towards more dynamic and responsive applications, the demand for GraphQL is steadily increasing, challenging the traditional REST paradigm. IBM continues advancing enterprise-grade API management and scalable cloud integration technologies supporting healthcare and pharmaceutical applications. Industry estimates suggest that more than 70% of web-based enterprise applications globally rely on RESTful APIs due to their scalability, interoperability, and lower development complexity, strengthening their dominance across digital healthcare and pharmaceutical ecosystems. ## Competitive Benchmarking The Api Market in India is characterized by a dynamic competitive landscape, driven by rapid technological advancements and increasing demand for digital solutions. Major players such as Tata Consultancy Services (IN), Infosys (IN), and Wipro (IN) are at the forefront, each adopting distinct strategies to enhance their market positioning. Tata Consultancy Services (IN) focuses on innovation through significant investments in research and development, aiming to lead in AI and machine learning applications. Infosys (IN), on the other hand, emphasizes strategic partnerships, particularly in cloud services, to bolster its service offerings. Wipro (IN) is actively pursuing mergers and acquisitions to expand its capabilities and market reach, thereby intensifying competition among these key players.   The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance customer engagement. Localizing manufacturing and supply chain optimization are prevalent strategies, allowing firms to respond swiftly to market demands. The competitive structure of the Api Market appears moderately fragmented, with a mix of established players and emerging startups, collectively influencing market dynamics and driving innovation.   In December 2025, Tata Consultancy Services (IN) announced a strategic partnership with a leading cloud provider to enhance its digital transformation services. This collaboration is poised to strengthen TCS's position in the cloud computing segment, enabling it to offer more comprehensive solutions to clients. The strategic importance of this partnership lies in its potential to accelerate TCS's growth trajectory in a rapidly evolving digital landscape.   In November 2025, Infosys (IN) launched a new AI-driven analytics platform aimed at improving operational efficiency for its clients. This initiative underscores Infosys's commitment to leveraging cutting-edge technology to deliver value-added services. The introduction of this platform is likely to enhance client satisfaction and retention, positioning Infosys favorably against its competitors.   In October 2025, Wipro (IN) completed the acquisition of a niche software firm specializing in cybersecurity solutions. This acquisition is strategically significant as it allows Wipro to expand its service portfolio and address the growing demand for cybersecurity in the digital age. By integrating these capabilities, Wipro is likely to enhance its competitive edge and attract new clients seeking robust security solutions.   As of January 2026, the Api Market is witnessing trends such as increased digitalization, a focus on sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. Companies that can effectively leverage these trends are likely to secure a stronger foothold in the market. ## Recent News & Developments - **Q2 2024: Lupin launches generic version of Spiriva in India** Lupin announced the launch of its generic version of Spiriva (Tiotropium Bromide Inhalation Powder) in India, expanding its respiratory portfolio and strengthening its position in the domestic API market. - **Q2 2024: Sun Pharma receives US FDA approval for generic drug manufactured in India** Sun Pharmaceutical Industries received approval from the US FDA for its generic version of a key cardiovascular drug, manufactured at its Indian API facility, marking a significant regulatory milestone. - **Q3 2024: Dr. Reddy’s Laboratories opens new API manufacturing facility in Hyderabad** Dr. Reddy’s Laboratories inaugurated a new API manufacturing plant in Hyderabad to boost production capacity and support global supply chains. - **Q3 2024: Aurobindo Pharma acquires API assets from Veritaz Healthcare** Aurobindo Pharma completed the acquisition of select API manufacturing assets from Veritaz Healthcare, aiming to enhance its product portfolio and manufacturing capabilities. - **Q4 2024: Biocon partners with Syngene to develop novel APIs for oncology** Biocon announced a strategic partnership with Syngene International to co-develop and manufacture novel APIs targeting oncology therapeutics. - **Q4 2024: Glenmark Pharmaceuticals receives DCGI approval for new API facility in Gujarat** Glenmark Pharmaceuticals received approval from the Drug Controller General of India (DCGI) for its newly constructed API manufacturing facility in Gujarat. - **Q1 2025: Cipla secures major API supply contract with European pharma company** Cipla signed a multi-year API supply agreement with a leading European pharmaceutical company, strengthening its export business. - **Q1 2025: Alkem Laboratories raises $100 million in funding to expand API production** Alkem Laboratories completed a $100 million funding round to support the expansion of its API manufacturing operations in India. - **Q2 2025: Zydus Lifesciences launches new API for diabetes treatment** Zydus Lifesciences introduced a new API for diabetes management, aiming to address growing demand in both domestic and international markets. - **Q2 2025: Laurus Labs announces partnership with global biotech firm for API innovation** Laurus Labs entered into a partnership with a global biotech company to co-develop innovative APIs for next-generation therapeutics. - **Q3 2025: Torrent Pharmaceuticals appoints new CEO to lead API division** Torrent Pharmaceuticals announced the appointment of a new CEO for its API division, signaling a strategic focus on growth and innovation. - **Q3 2025: Strides Pharma Science receives regulatory approval for new API manufacturing unit** Strides Pharma Science obtained regulatory clearance for its newly established API manufacturing unit, expanding its production footprint in India. ## Report Scope | MARKET SIZE 2024 | 8.0(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 8.33(USD Billion) | | MARKET SIZE 2035 | 12.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.76% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Tata Consultancy Services (IN), Infosys (IN), Wipro (IN), HCL Technologies (IN), Tech Mahindra (IN), Cognizant Technology Solutions (US), Accenture (IE), IBM (US), Oracle (US) | | Segments Covered | Application, End Use Industry, Deployment Model, Type of API, Technology | | Key Market Opportunities | Growing demand for sustainable and innovative active pharmaceutical ingredients in the market. | | Key Market Dynamics | Rising demand for active pharmaceutical ingredients drives innovation and competition in India's pharmaceutical sector. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India API market as of 2024?** A: The India API market was valued at 8.0 USD Billion in 2024. **Q: What is the projected market size for the India API market by 2035?** A: The projected valuation for the India API market is expected to reach 12.0 USD Billion by 2035. **Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 3.76%. **Q: Which companies are considered key players in the market?** A: Key players in the market include Tata Consultancy Services, Infosys, Wipro, HCL Technologies, Tech Mahindra, Cognizant Technology Solutions, Accenture, IBM, and Oracle. **Q: How does the India API market segment by application?** A: The India API market segments by application include Web Services, Mobile Applications, Cloud Computing, Data Integration, and Microservices. **Q: What are the projected values for the Cloud Computing segment in the market?** A: The Cloud Computing segment in the market is projected to grow from 2.0 USD Billion to 3.0 USD Billion. **Q: What is the expected growth for the Healthcare segment in the India API market?** A: The Healthcare segment is anticipated to grow from 2.0 USD Billion to 3.0 USD Billion in the India API market. **Q: What types of APIs are included in the market analysis?** A: The types of APIs included in the market analysis are Open API, Internal API, Partner API, and Composite API. **Q: What is the projected growth for RESTful APIs in the market?** A: RESTful APIs are projected to grow from 3.2 USD Billion to 4.8 USD Billion in the market. **Q: How is the India API market expected to evolve in terms of deployment models?** A: The India API market is expected to evolve with On-Premises, Cloud-Based, and Hybrid deployment models, with Cloud-Based projected to grow from 3.2 USD Billion to 5.0 USD Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-api-market-21362*